Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Needle revision with sub-conjunctival bevacizumab for late trabeculectomy failure

Poster Details

First Author: N.Anand UK

Co Author(s):                  

Abstract Details



Purpose:

To report outcomes of needle revision of trabeculectomy blebs with subconjunctival Bevacizumab.

Setting:

Calderdale & Huddersfield NHS Trust, West Yorkshire , UK

Methods:

Retrospective case- series of eyes undergoing needle revision (NR) with adjunctive subconjunctival Bevacizumab.( 2.5mg in 0.1 ml). All procedures were performed 6 months after trabeculectomy by the same surgeon. Success was defined as an IOP ?18 mmHg and a 20% decrease from baseline IOP with no medications.

Results:

15 eyes of 14 patients were included. The interval between trabeculectomy and NR was 58.5 ±52.9 (range 7-156) months. Mean follow-up after NR was 22.1 ±8.6 (range 12-36) months. Mean IOP at decision to perform NR was 23.0 ±5.0 mmHg. Success by last follow-up was achieved in 9 eyes (60%). Kaplan-Meir success rates were 57.1 % (36.3 – 89.9%, 95% Confidence Intervals) at one year and 40.8% (21.3-78.4, 95% CIs) at 2 years after NR. At last follow-up 4 (26.7%) eyes needed medications to control IOP. Subsequent procedures to control IOP were selective laser trabeculoplasty in 2 eyes and trabeculectomy with MMC and NR with MMC in 1 eye each. One eye each had a shallow anterior chamber and hyphema in the first week after NR.

Conclusions:

NR with subconjunctival Bevacizumab was safe and effective in lowering IOP in majority of eyes in with delayed trabeculectomy failure.

Financial Disclosure:

NONE

Back to previous